Supervised vs. Home Schroth Exercise in AIS

August 31, 2026 updated by: Mesut Arslan, Bitlis Eren University

Comparative Effectiveness of Supervised vs. Home-Based Schroth Exercises in Adolescent Idiopathic Scoliosis: A Randomized Controlled Trial

This study aims to compare the effectiveness of supervised Schroth exercises versus a home-based exercise program in adolescents with Adolescent Idiopathic Scoliosis (AIS).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Adolescent Idiopathic Scoliosis (AIS) is a three-dimensional spinal deformity that develops in children aged 10-18, affecting approximately 0.47% to 12% of this population. If left untreated, curves between 10° and 45° may progress, leading to pain, breathing difficulties, postural problems, and reduced quality of life. Although bracing and surgery are traditional options, they have limitations. Physiotherapeutic scoliosis-specific exercises (PSSE), particularly the Schroth method, are increasingly recommended as a first-line conservative treatment.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
62

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey (Türkiye)
    • Istanbul
      • Siliviri, Istanbul, Turkey (Türkiye), 34570
        • Recruiting
        • Silivri Devlet Hastanesi, Fizik Tedavi Ünitesi
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of Adolescent Idiopathic Scoliosis (idiopathic etiology)
  • Age between 10 and 18 years
  • Cobb angle between 10° and 45°
  • Able to participate in a 5-day/week exercise program (supervised or home-based)
  • Patient and parent/guardian provide written informed consent
  • Sufficient cooperation to comply with the study protocol and complete assessments

Exclusion Criteria:

  • Non-idiopathic scoliosis (neuromuscular, congenital, functional, etc.)
  • Prior or planned spinal surgery
  • Neurological, rheumatological, metabolic, or cardiopulmonary disease that would interfere with participation
  • Brace treatment within the last 6 months or planned during the study
  • Regular scoliosis-specific exercise (more than 2 days/week) within the last 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Supervised Schroth Exercise Group (SSEG)
Participants in this group will receive the exercise program under direct, one-on-one supervision by a physiotherapist. This is a purely physical exercise intervention. No drugs or devices are used as part of the intervention. Only the Schroth exercise program is administered.
Other: Supervised Schroth Exercise
60-minute Schroth exercise sessions, 5 days/week for 12 weeks, delivered under one-on-one physiotherapist supervision. Includes 3D auto-correction, rotational breathing, postural stabilization, and curve-specific exercises (shoulder counter-pull, muscle cylinder, side-lying, sailing, prominent hip, Schroth walking)
Active Comparator: Home Exercise Program Group (HEPG)
Participants in this group will be provided with an individualized home exercise program that matches the supervised group in terms of principles, content, and duration. This is a purely physical exercise intervention. No drugs or devices are used as part of the intervention. Only the Schroth exercise program is administered.
Other: Home-Based Schroth Exercise
Same 60-minute Schroth exercise program, 5 days/week for 12 weeks, performed at home without direct physiotherapist supervision. Participants receive initial instruction and an individualized exercise booklet.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Cobb Angle
Time Frame: Baseline and 3 months post-intervention
Change in the primary curve Cobb angle measured on standing posteroanterior full-spine radiographs, assessed at baseline and 3 months post-intervention.
Baseline and 3 months post-intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Trunk Rotation Angle (ATR)
Time Frame: Baseline and 12 weeks
Change in angle of trunk rotation measured using a scoliometer during the Adam's Forward Bend Test.
Baseline and 12 weeks
Change in Thoracic Kyphosis
Time Frame: Baseline and 12 weeks
Change in thoracic kyphosis angle measured using an inclinometer at T1-T2 and T12-L1 levels.
Baseline and 12 weeks
Change in Lumbar Lordosis
Time Frame: Baseline and 12 weeks
Change in lumbar lordosis angle measured using an inclinometer at T12-L1 and S2-S3 levels.
Baseline and 12 weeks
Respiratory Function assessed by Spirometry (FVC, FEV1, FEV1/FVC, PEF, FEF25-75%)
Time Frame: Baseline and 12 weeks
Respiratory function will be assessed using a spirometry device. The following parameters will be recorded and analyzed: Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), the FEV1/FVC ratio, Peak Expiratory Flow (PEF), and Forced Expiratory Flow at 25-75% of FVC (FEF25-75%).
Baseline and 12 weeks
Change in Pain Level
Time Frame: Baseline and 12 weeks
Change in musculoskeletal pain/discomfort assessed using the Turkish-validated Cornell Musculoskeletal Discomfort Questionnaire (T-CMDQ) [19]. The questionnaire evaluates discomfort in 18 body regions over the past week across three dimensions: frequency, severity, and functional impact on daily activities. A risk score is calculated for each body region by multiplying these three parameters. For bilaterally assessed regions, the higher of the two side-specific scores is used in the analysis. Higher scores indicate worse outcomes.
Baseline and 12 weeks
Change in Quality of Life
Time Frame: Baseline and 12 weeks
Change in health-related quality of life assessed using the Turkish-validated Scoliosis Research Society-22 (SRS-22) questionnaire. The questionnaire consists of five domains: function, pain, self-image, mental health, and treatment satisfaction. Each item is scored from 1 (worst) to 5 (best); domain and total scores range from 1 to 5. Higher scores indicate better outcomes. The treatment satisfaction domain will be assessed only at 12 weeks; other domains assessed at both baseline and 12 weeks.
Baseline and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bitlis Eren University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 31, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 31, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 31, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 15, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 20, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 21, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 1, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 31, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • E.9290

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings